Uterine and Tubal Lavage for Earlier Cancer Detection Using an Innovative Catheter: A Feasibility and Safety Study. Issue 9 (1st November 2018)

• Record Type: Journal Article
• Authors: Maritschnegg, Elisabeth; Heitz, Florian; Pecha, Nina; Bouda, Jirí; Trillsch, Fabian; Grimm, Christoph; Vanderstichele, Adriaan; Agreiter, Christiane; Harter, Philipp; Obermayr, Eva; Vergote, Ignace; Zeillinger, Robert; Speiser, Paul
• Is Part Of: International journal of gynecological cancer. Volume 28:Issue 9(2018)
• Page Start: 1692
• Page End: 1698
• Publication Date: 2018-11-01
• Subjects: Early diagnosis -- High-grade serous cancer -- Catheter -- Uterine lavage -- Feasibility study; Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1097/IGC.0000000000001361
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: Poor survival of high-grade serous pelvic cancer is caused by a lack of effective screening measures. The detection of exfoliated cells from high-grade serous pelvic cancer, or precursor lesions, is a promising concept for earlier diagnosis. However, collecting those cells in the most efficient way while fulfilling all requirements for a screening approach is a challenge. We introduce a new catheter for uterine and tubal lavage (UtL) and the clinical evaluation of its performance. Methods/Materials: In study I, the clinical feasibility of the UtL using the new catheter was examined in 93 patients admitted for gynecologic surgery under general anesthesia. In study II, the safety of the UtL procedure was assessed. The pain during and after the UtL performed under local anesthesia was rated on a visual analog scale by 22 healthy women. Results: In study I, the UtL was carried out successfully in 92 (98.9%) of 93 cases by 16 different gynecologists. It was rated as easy to perform in 84.8% of patients but as rather difficult in cancer patients (odds ratio, 5.559; 95% confidence interval, 1.434–21.546; P = 0.007). For benign conditions, dilatation before UtL was associated with menopause status (odds ratio, 4.929; 95% confidence interval, 1.439–16.884; P = 0.016). In study II, the pain during UtL was rated with a median visual analog scale score of 1.6. During a period of 4 weeks after UtL, none of the participants had to use medication or developed symptoms requiring medical attention. The UtL took 6.5 minutes on average. The amount of extracted DNA was above the lower limit for a sensitive, deep-sequencing mutation analysis in all cases. Conclusions: Our studies demonstrate that the UtL, using the new catheter, is a safe, reliable, and well-tolerated procedure, which does not require elaborate training. Therefore, UtL fulfils all prerequisites to be used in a potential screening setting.